SU1650140A1 - Method of treatment of pneumonia - Google Patents

Abstract

This invention relates to medicine, in particular to pulmonology. The goal is to reduce the treatment time for patients with tuberculosis and pneumonia by normalizing lung surfactants. For this, the introduction of a-tocopherol inhalations of ultrasonic aerosols with a contractile is additionally included in the traditional complex treatment.

Description

This invention relates to medicine, in particular to pulmonology.

The purpose of the invention is to reduce the treatment time for patients with tuberculosis and pneumonia by normalizing lung surfactants.

The method is carried out as follows.

After establishing violations in the lung surfactant system, the patient received «-tocopherol acetate at a dose of 8–10 mg / kg body weight for 20–30 days in combination with ultrasonic aerosols inhalation of contractive at a dose of 2500–5000 AU DU. 10-15 days.

Repeated courses are conducted in 1.0-1.5 months.

PRI me R 1. Patient K., 33 years old, body weight 61 kg, diagnosis: Infiltrative tuberculosis of the upper lobe of the right lung in the disintegration phase, BK +, subfebrility. Treatment with isoniazid, benemycin, streptomycin according to the traditional scheme, vitamins of group B. Additional

A-tocopherol acetate was administered in a dose of 600 mg orally (2 capsules 3 times a day) for 30 days and UGA counter-dose in a dose of 5000 At U for 15 days.

The state of the surface activity of pulmonary surfactants was judged by the indicators of the function of external respiration characterizing the pulmonary excretion: lung capacity (VOL) and inspiratory reserve volume (RON); stability index (IC) and the percentage of fatty acids of phospholipids in the condensate of exhaled air.

Analysis of the data showed that the inclusion in the complex treatment of the combination of a-tocopherol acetate and contrikal leads to the normalization of the performance of the VC, RON., IC and the percentage of fatty acids in the condensate of exhaled air.

A repeated course of correction of surfactants was not required. After two weeks, the symptoms of intoxication disappeared, and after three weeks they stopped listening to wheezing in the lungs. One month later, C became normal.

01

with

Os

ate about

Ј o

the morphological composition of the blood and the erythrocyte sedimentation rate, bacterial secretion ceased. After two months of treatment, the resorption of infiltrative changes and the healing of the decay cavity in the lungs was radiographically observed. After 5 months of treatment, the patient is sent for sanatorium-resort treatment.

Example 2. Patient L., 41 years old, 79 kg body weight, diagnosis: Nonspecific pneumonia of the middle lobe of the right lung. Were treated with antibiotics, sulfonamides, broncho-and mucolytics, multivitamins. In addition, the patient received o-tocopherol acetate 200 mg orally 3 times a day and inhalation of UZA kontrikala 5000 At U D for 10 days.

As a result of treatment, the symptoms of intoxication disappeared after 5 days, cough and wheezing in the lungs after 10 days, the blood test was normalized after 12 days. X-ray after 14 days showed complete resorption of infiltrative changes in the right lung. After 15 days, the patient was discharged in satisfactory condition for work.

The results of the study of the respiratory function, IP and fatty acid composition of phospholipids in the condensate of exhaled air showed that the inclusion in the complex treatment of a-tocopherol acetate and contrakal after 2 weeks leads to the normalization of indicators of respiratory function, IC and the percentage of fatty acids in the condensate of exhaled air.

With normal values or minor changes in the indices characterizing the surface activity of lung surfactants, the therapy used does not have a significant effect on the correction of these indices.

The proposed method for the correction of surfactants (main group) was tested in complex treatment in 20 patients with tuberculosis and in 12 non-specific pneumonia. The control group consisted of 41 patients with pulmonary tuberculosis and 12 patients with nonspecific pneumonia, who took the same anti-tuberculosis drugs and nonspecific antibiotics as in the main group using USA inhalation with a mixture of hydrocortisone with heparin and glucose.

Studies have shown that the use of α-tocopherol in combination with contraction in the complex treatment of patients with tuberculosis and nonspecific pneumonia more effectively normalizes the indicators of respiratory function, surface activity and fatty acid composition of the exhaled breath surfactant surfactant, which accelerates the disappearance of intoxication symptoms, resorption of infiltrative-pneumonic changes, healing of disintegration cavities in the lungs and shortening the duration of inpatient treatment. All this is the effectiveness of the treatment.

In the control group of patients, where the previously known method of correction of surfactants was applied, in patients with pulmonary tuberculosis, the closure of decay cavities was observed in 80% of cases (20 out of 25), the cessation of bacterial secretion - 88% (in 36 out of 41). The average duration of treatment for patients with pneumonia was 22 ± 1.5 bed-days.

In the group of patients where correction of surfactants by the proposed method was used in the complex therapy, the closure

0 decay cavities occurred and 89.5% (in 17 out of 19), cessation of bacteria in 100% of cases, which is respectively 9.5 and 12% more and 1-1.5 months earlier than in the control group. Average duration

5 stays on the patient's bed with pneumonia amounted to 17.4 bed-days, which is 5 days less than in the control group.

The method is simple to perform and can be recommended for use in

0 widespread clinical practice.

Claims (1)

The invention of the method of treatment of inflammatory diseases of the lungs, including the introduction of drugs affecting 5. A surfactant system of the lungs, characterized in that, in order to shorten the treatment time for patients with tuberculosis and pneumonia, due to the normalization of surfactants, a contrical is introduced in the form of inhalations. 0 ultrasonic aerosols in combination with the introduction of a-tocopherol.